Premium Reports
Interoperability (Plug and Play) 2006

Interoperability (Plug and Play) 2006

| Read Time: Unknown

Doing a study on interoperability is like traveling with children who ask all too frequently “Are we there yet”? The answer, in the case of interoperability is obviously "no"--but how far are we?

The Interoperability Plug and Play report answers questions such as "How well do today’s healthcare software products interoperate with another vendor’s software products central to meeting the typical provider organization’s goals?" and "Which vendors/products/functions are best at interfacing (interoperating) with others?"

Select Study Findings

  • Overall, scoring is below the mid-point (4.0 on a 9 point scale), regarding how today’s vendors plug and play with others.
  • The largest organizations (over 1,000 beds) reported they were least likely to be meeting their interoperability goals (3.4 on the 9 point scale).
  • Over 60 percent of Eclipsys, Epic, GE and McKesson participants report that they are over half way to reaching their interoperability goals. No one reported having achieved 100 percent of their interoperability goals (actual range reported was zero percent to 90 percent).

Vendors Included in the Study

AGFA, ALLSCRIPTS/A4, CERNER, QUOVADX (CLOVERLEAF), ECLIPSYS, EMAGEON, EPIC, FUJI, GE/IDX, INTERSYSTEMS, INTRANEXUS, KEANE, KRONOS, LAWSON, MCKESSON, MEDITECH, MEDIWARE, MISYS, NEO INTEGRATE, ORION, PER-SE , PHILIPS, PICIS, PYXIS, QUADRAMED, QUOVADX, SUN (SEEBEYOND), SIEMENS, SIS, SYBASE

Want to see full details?

Create an Account
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2019 KLAS Enterprises, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.